SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
Open Access
- 19 November 2022
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 59 (4) , 192-197
Abstract
No abstract availableKeywords
Funding Information
- ZonMw
This publication has 64 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in IsraelFrontiers in Immunology, 2021
- The outcome of COVID‐19 in patients with hematological malignancyJournal of Medical Virology, 2020
- SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate SeroprevalenceThe Journal of Infectious Diseases, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemiaJournal of Allergy and Clinical Immunology, 2020
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recoverPediatric Allergy and Immunology, 2020
- Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019
- Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019
- Immune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationFrontiers in Immunology, 2016